The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Special Research Initiatives - Grant ID: SR0354474
Funder
Australian Research Council
Funding Amount
$30,000.00
Summary
Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The ini ....Metals in Medicine. Metal-based drugs account for several billion dollars of pharmaceutical sales worldwide, but proportionally much less research and development has focussed on this area than organic drugs. Australia has played a pivotal role in the early development of metal-based pharmaceuticals, which remains a research strength. The dual aims of the initiative are to provide a network for a vibrant industry based around metals in medicine and to improve the health of Australians. The initiative will foster national and international cross-disciplinary collaborations to address the impediments holding back Australia's potential to take full advantage of our research strength in metals in medicine.Read moreRead less
Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer. Identifying and treating malignant cancers is one of the major challenges facing the scientific and medical communities. In order to minimise side effects that accompany most treatments of cancer it is necessary to find ways of targeting the therapy to tumours and away from healthy organs. A difference between tumours and healthy tissues is the amount of the proteins (calle ....Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer. Identifying and treating malignant cancers is one of the major challenges facing the scientific and medical communities. In order to minimise side effects that accompany most treatments of cancer it is necessary to find ways of targeting the therapy to tumours and away from healthy organs. A difference between tumours and healthy tissues is the amount of the proteins (called MMPs) that tumours use to break out of their surroundings, to break into and out of the blood system, and to establish new colonies of cancer cells or metastases. This difference also distinguishes the most aggressive cancers. The purpose of this project is to develop means of identifying and targeting cancers using molecules that bind to these MMP proteins.Read moreRead less
Nanotherapeutics: nanoparticles with high specificity for the delivery and controlled release of drugs. This technology will deliver therapeutic drugs and/or MRI contrast agents to individual diseased cells with very high specificity and selectivity. The cells can be interogated to determine when they are "loaded" and the site of the "loaded" cells precisely determined. Drugs can be released photochemically. The administered dosage can be decreased with no loss of efficacy, and side effects re ....Nanotherapeutics: nanoparticles with high specificity for the delivery and controlled release of drugs. This technology will deliver therapeutic drugs and/or MRI contrast agents to individual diseased cells with very high specificity and selectivity. The cells can be interogated to determine when they are "loaded" and the site of the "loaded" cells precisely determined. Drugs can be released photochemically. The administered dosage can be decreased with no loss of efficacy, and side effects reduced. Read moreRead less